Watine J, Charet J C
Laboratoire de biologie polyvalente, Hôpital Général, Rodez.
Rev Mal Respir. 1999 Apr;16(2):139-49.
The American Thoracic Society (ATS) and the European Respiratory Society (ERS) do not recommend routine tumor marker assay for screening, staging or evaluation of non-small-cell lung cancer (NSCLC). In contrast to this position, the statement of the French society of pneumology (Société de Pneumologie de Langue Française, SPLF) suggests such assays may be useful for prognostic evaluation of NSCLC (and certainly so before treatment) and that the usefulness of serum CEA (carcino-embryonic antigen) measurements before and after treatment is not clearly excluded. Our own review of the literature indicates that other routine tests less expensive than tumor markers such as LDH, prothrombin time, calcium, blood cell counts and even serum proteins might, alone or in combination, have a prognostic significance similar to, or even higher than, tumor markers. Since routine clinical laboratories have to set priorities for useful analyses, a clear reading of the biomedical literature suggests that it is not currently necessary to routinely measure serum tumor markers (including Cyfra 21-1) for the prognostic evaluation of NSCLC patients.
美国胸科学会（ATS）和欧洲呼吸学会（ERS）不建议将常规肿瘤标志物检测用于非小细胞肺癌（NSCLC）的筛查、分期或评估。与这一立场相反，法国肺病学会（Société de Pneumologie de Langue Française, SPLF）的声明表明，此类检测可能对NSCLC的预后评估有用（当然在治疗前是这样），并且血清癌胚抗原（CEA）治疗前后测量的有用性并未被明确排除。我们自己对文献的综述表明，其他比肿瘤标志物成本更低的常规检测，如乳酸脱氢酶（LDH）、凝血酶原时间、钙、血细胞计数甚至血清蛋白，单独或联合使用可能具有与肿瘤标志物相似甚至更高的预后意义。由于常规临床实验室必须为有用的分析设定优先级，对生物医学文献的清晰解读表明，目前没有必要为NSCLC患者的预后评估常规检测血清肿瘤标志物（包括细胞角蛋白19片段（Cyfra 21-1））。
